These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 21421040)

  • 1. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
    Saxena V; Panicucci R; Joshi Y; Garad S
    J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
    Ioset JR; Chang S
    Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic therapeutic peptides: science and market.
    Vlieghe P; Lisowski V; Martinez J; Khrestchatisky M
    Drug Discov Today; 2010 Jan; 15(1-2):40-56. PubMed ID: 19879957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomics and drug discovery.
    Van Osta P; Ver Donck K; Bols L; Geysen J
    Cytometry A; 2006 Mar; 69(3):117-8. PubMed ID: 16496374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target selection and pharma industry productivity: what can we learn from technology S-curve theory?
    Brown D
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):414-8. PubMed ID: 16889225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.